Rodman & Renshaw Begins Coverage on INmune Bio (NASDAQ:INMB)

Investment analysts at Rodman & Renshaw initiated coverage on shares of INmune Bio (NASDAQ:INMB) in a report issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $23.00 price target on the stock. Rodman & Renshaw’s target price suggests a potential upside of 153.86% from the stock’s previous close.

Separately, Alliance Global Partners initiated coverage on INmune Bio in a report on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, INmune Bio has an average rating of “Buy” and an average price target of $20.75.

INmune Bio Trading Up 13.0 %

INMB stock opened at $9.06 on Tuesday. The stock has a 50-day moving average price of $5.54 and a two-hundred day moving average price of $6.06. The stock has a market cap of $200.86 million, a PE ratio of -4.16 and a beta of 1.78. INmune Bio has a 1 year low of $4.32 and a 1 year high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same quarter in the prior year, the company posted ($0.48) earnings per share. On average, analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of INMB. Financial Advocates Investment Management grew its holdings in INmune Bio by 14.8% during the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after purchasing an additional 2,000 shares during the period. Jane Street Group LLC bought a new position in INmune Bio during the third quarter worth about $79,000. Sanctuary Advisors LLC bought a new position in INmune Bio during the third quarter worth about $113,000. Rhumbline Advisers bought a new position in INmune Bio during the second quarter worth about $121,000. Finally, Barclays PLC grew its holdings in INmune Bio by 601.9% during the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after purchasing an additional 24,906 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.